Unlimited Bio, a leading biotechnology company focused on preventive and combinatorial aging interventions, today publicly announced a landmark partnership with BioViva, led by longevity pioneer Liz Parrish. This alliance grants Unlimited Bio an exclusive license to four advanced adeno-associated virus (AAV)–mediated gene therapies originally developed by BioViva. The collaboration is designed to fast-track UB’s preventive gene therapy program, combining multiple therapeutic modalities into a cohesive clinical trial protocol.
BioViva’s Track Record:
Liz Parrish, CEO of BioViva, is widely recognized for self-administration of experimental gene therapies (e.g., telomerase in 2015).
Over the past decade, BioViva has built proprietary protocols around AAV-delivered genes targeting hallmark aging mechanisms.
Unlimited Bio’s collaboration with BioViva is arguably the boldest human gene therapy initiative in the longevity space to date. By leveraging four distinct AAV-delivered therapeutics targeting telomeres, muscle mass, systemic anti-aging factors, and mitochondrial health, UB seeks to validate a multi-modal intervention in humans for the first time. Should the trial demonstrate even partial success (e.g., safety with robust biomarker shifts), it could trigger a paradigm shift in how biotech approaches aging, opening doors to follow-on combination therapies and downstream commercialization.